Patents by Inventor Aichen Wang

Aichen Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180325366
    Abstract: A terahertz endoscope suitable for intestinal tract lesion inspection and an inspection method are provided. The terahertz endoscope includes a combined tube body inserted into an intestinal tract, a terahertz signal enhancement module, a terahertz inspection module, and a real-time imaging module. The combined tube body mainly includes a sleeve tube (6), a sleeve head (7) and a hemispherical glass cover (8). The terahertz signal enhancement module mainly includes a tunable laser (2) and an optical fiber (9) installed in the sleeve tube (6). The terahertz inspection module mainly includes a terahertz wave detector (4), a terahertz wave transmitter (5), as well as a first stainless steel metal wire (12) and a second stainless steel metal wire (13) installed in the combined tube body.
    Type: Application
    Filed: April 16, 2016
    Publication date: November 15, 2018
    Applicant: ZHEJIANG UNIVERSITY
    Inventors: Lijuan Xie, Chen Wang, Yibin Ying, Aichen Wang, Yuxin Huang
  • Patent number: 9809589
    Abstract: The present invention belongs to the technical field of medicines, and relates to a crystal form of a compound used as a mineralocorticoid receptor antagonist and a preparation method therefor, and in particular, to a method for preparing a compound 2-chloro-4-[(3S,3aR)-3-cyclopentyl-7-(4-hydroxypiperidin-1-carbonyl)-3,3a,4,5-tetrahydro-2H-pyrazolo[3,4-f]quinolin-2-yl]benzonitrile of formula (1); a crystal form thereof, a preparation method for the crystal form, and the use of the crystal form in the preparation of drugs for the treatment and/or prevention of renal injury or cardiovascular diseases.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: November 7, 2017
    Assignee: KBP BIOSCIENCES CO., LTD.
    Inventors: Chen Jiang, Aichen Wang, Dedong Zhang
  • Publication number: 20170136023
    Abstract: The invention relates to a quinazoline derivative represented by the general formula (I), a pharmaceutical acceptable salt and a stereoisomer thereof as tyrosine kinase inhibitor, wherein R1, R2, R3, R3?, R4, R5, R6, X, L, T, Z and q are as defined in the specification. The invention also relates to a process for preparing the same, a pharmaceutical composition and a pharmaceutical formulation containing the derivative, use of the derivative for treating excessive proliferative diseases and chronic obstructive pulmonary disease and use of the derivative in the manufacture of a medicament for treating excessive proliferative diseases and chronic obstructive pulmonary disease.
    Type: Application
    Filed: January 30, 2017
    Publication date: May 18, 2017
    Applicant: Xuanzhu Pharma Co., Ltd.
    Inventors: Frank Wu, Aichen Wang
  • Patent number: 9642851
    Abstract: The present invention relates to a compound represented by general formula (I), a method for preparing said compound, a pharmaceutical formulation containing said compound, and the use of said compound in manufacture of a medicament for treating or preventing the fibrous degeneration disease and treating the excessive proliferation disease: wherein ring A, X, R1, R2, R3, R4, R5, R6, R7, R8, R9, a, b and n are defined as those in the description.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: May 9, 2017
    Assignee: KBP BioSciences Co., Ltd.
    Inventors: Hoyin Lo, Aichen Wang, Qian Zhang
  • Patent number: 9586939
    Abstract: The invention relates to a quinazoline derivative represented by the general formula (I), a pharmaceutical acceptable salt and a stereoisomer thereof as tyrosine kinase inhibitor, wherein R1, R2, R3, R3?, R4, R5, R6, X, L, T, Z and q are as defined in the specification. The invention also relates to a process for preparing the same, a pharmaceutical composition and a pharmaceutical formulation containing the derivative, use of the derivative for treating excessive proliferative diseases and chronic obstructive pulmonary disease and use of the derivative in the manufacture of a medicament for treating excessive proliferative diseases and chronic obstructive pulmonary disease.
    Type: Grant
    Filed: May 28, 2012
    Date of Patent: March 7, 2017
    Assignee: XUANZHU PHARMA CO., LTD.
    Inventors: Frank Wu, Aichen Wang
  • Patent number: 9487545
    Abstract: The present invention relates to a fused ring-containing oxazolidinone compound shown by general formula (I), a pharmaceutically acceptable salt thereof and a stereoisomer thereof, wherein R1, R2, R3, R4, R5, R6, A, B and C are as defined in the description. The present invention further relates to a method for preparing the compound, a pharmaceutical composition and a pharmaceutical formulation comprising the compound, and a use of the compound for the manufacture of a medicament for the treatment and/or prevention of infectious diseases and a use for the treatment and/or prevention of infectious diseases.
    Type: Grant
    Filed: September 29, 2012
    Date of Patent: November 8, 2016
    Assignee: Xuanzhu Pharma Co., Ltd.
    Inventors: Hui Zhang, Aichen Wang
  • Patent number: 9359344
    Abstract: The present invention relates to a biaryl heterocycle substituted oxazolidinone antibacterials shown by general formula (I), a pharmaceutically acceptable salt thereof, an isomer or a prodrug thereof, wherein R1, R2, R3, R4, R5, A and B are as defined in the description. The present invention further relates to a method for preparing the compound, a pharmaceutical composition and a pharmaceutical formulation comprising the compound, and a use of the compound in the manufacture of a medicament for the treatment and/or prevention of infectious diseases and a use for the treatment and/or prevention of infectious diseases.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: June 7, 2016
    Assignee: Xuanzhu Pharma Co., Ltd.
    Inventors: Frank Wu, Aichen Wang
  • Patent number: 9359371
    Abstract: Disclosed are bicyclic group substituted pyrimidine compounds, pharmaceutical acceptable salts thereof or stereoisomers thereof. Also disclosed are preparation methods, pharmaceutical formulations, and pharmaceutical compositions of the compounds, and use of the compounds, pharmaceutical formulations, and pharmaceutical compositions for preparing a medicament for treating and/or preventing sexual dysfunction diseases and diseases with lower urinary tract symptoms.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: June 7, 2016
    Assignee: XUANZHU PHARMA CO., LTD.
    Inventors: Frank Wu, Aichen Wang
  • Publication number: 20150336950
    Abstract: The present invention belongs to the technical field of medicines, and relates to a crystal form of a compound used as a mineralocorticoid receptor antagonist and a preparation method therefor, and in particular, to a method for preparing a compound 2-chloro-4-[(3S,3aR)-3-cyclopentyl-7-(4-hydroxypiperidin-1-carbonyl)-3,3a,4,5-tetrahydro-2H-pyrazolo[3,4-f]quinolin-2-yl]benzonitrile of formula (1); a crystal form thereof, a preparation method for the crystal form, and the use of the crystal form in the preparation of drugs for the treatment and/or prevention of renal injury or cardiovascular diseases.
    Type: Application
    Filed: December 23, 2013
    Publication date: November 26, 2015
    Applicant: KBP BIOSCIENCES CO., LTD.
    Inventors: Chen JIANG, Aichen WANG, Dedong ZHANG
  • Publication number: 20150306095
    Abstract: The present invention relates to a compound represented by general formula (I), a method for preparing said compound, a pharmaceutical formulation containing said compound, and the use of said compound in manufacture of a medicament for treating or preventing the fibrous degeneration disease and treating the excessive proliferation disease: wherein ring A, X, R1, R2, R3, R4, R5, R6, R7, R8, R9, a, b and n are defined as those in the description.
    Type: Application
    Filed: December 6, 2013
    Publication date: October 29, 2015
    Applicant: KBP Biosciences Co., Ltd.
    Inventors: Hoyin Lo, Aichen Wang, Qian Zhang
  • Publication number: 20150232474
    Abstract: Disclosed are bicyclic group substituted pyrimidine compounds, pharmaceutical acceptable salts thereof or stereoisomers thereof. Also disclosed are preparation methods, pharmaceutical formulations, and pharmaceutical compositions of the compounds, and use of the compounds, pharmaceutical formulations, and pharmaceutical compositions for preparing a medicament for treating and/or preventing sexual dysfunction diseases and diseases with lower urinary tract symptoms.
    Type: Application
    Filed: August 14, 2013
    Publication date: August 20, 2015
    Inventors: Frank Wu, Aichen Wang
  • Patent number: 8980904
    Abstract: The present invention pertains to the field of medical technology, and particularly relates to a heterocyclic substituted pyrimidine compound represented by General Formula (I) and its pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and R5 are as defined in the description, the present invention also relates to a preparation method of the compound, a pharmaceutical composition containing the compound, and a use of the compound and the pharmaceutical composition in preparation of a medicine for enhancing a cGMP signal transduction function or a medicine for treating or preventing sexual dysfunction and diseases with lower urinary tract symptoms.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: March 17, 2015
    Assignee: Xuanzhu Pharma Co., Ltd.
    Inventors: Yongqian Wu, Aichen Wang
  • Publication number: 20140288063
    Abstract: The present invention pertains to the field of medical technology, and particularly relates to a heterocyclic substituted pyrimidine compound represented by General Formula (I) and its pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and R5 are as defined in the description, the present invention also relates to a preparation method of the compound, a pharmaceutical composition containing the compound, and a use of the compound and the pharmaceutical composition in preparation of a medicine for enhancing a cGMP signal transduction function or a medicine for treating or preventing sexual dysfunction and diseases with lower urinary tract symptoms.
    Type: Application
    Filed: July 19, 2012
    Publication date: September 25, 2014
    Applicant: Xuanzhu Pharma Co., Ltd.
    Inventors: Yongqian Wu, Aichen Wang
  • Publication number: 20140243288
    Abstract: The present invention relates to a fused ring-containing oxazolidinone compound shown by general formula (I), a pharmaceutically acceptable salt thereof and a stereoisomer thereof, wherein R1, R2, R3, R4, R5, R6, A, B and C are as defined in the description. The present invention further relates to a method for preparing the compound, a pharmaceutical composition and a pharmaceutical formulation comprising the compound, and a use of the compound for the manufacture of a medicament for the treatment and/or prevention of infectious diseases and a use for the treatment and/or prevention of infectious diseases.
    Type: Application
    Filed: September 29, 2012
    Publication date: August 28, 2014
    Inventors: Hui Zhang, Aichen Wang
  • Publication number: 20140235584
    Abstract: The present invention relates to a biaryl heterocycle substituted oxazolidinone antibacterials shown by general formula (I), a pharmaceutically acceptable salt thereof, an isomer or a prodrug thereof, wherein R1, R2, R3, R4, R5, A and B are as defined in the description. The present invention further relates to a method for preparing the compound, a pharmaceutical composition and a pharmaceutical formulation comprising the compound, and a use of the compound in the manufacture of a medicament for the treatment and/or prevention of infectious diseases and a use for the treatment and/or prevention of infectious diseases.
    Type: Application
    Filed: September 28, 2012
    Publication date: August 21, 2014
    Applicant: Xuanzhu Pharma Co., Ltd.
    Inventors: Frank Wu, Aichen Wang
  • Publication number: 20140161801
    Abstract: The invention relates to a quinazoline derivative represented by the general formula (I), a pharmaceutical acceptable salt and a stereoisomer thereof as tyrosine kinase inhibitor, wherein R1, R2, R3, R3?, R4, R5, R6, X, L, T, Z and q are as defined in the specification. The invention also relates to a process for preparing the same, a pharmaceutical composition and a pharmaceutical formulation containing the derivative, use of the derivative for treating excessive proliferative diseases and chronic obstructive pulmonary disease and use of the derivative in the manufacture of a medicament for treating excessive proliferative diseases and chronic obstructive pulmonary disease.
    Type: Application
    Filed: May 28, 2012
    Publication date: June 12, 2014
    Applicant: XUANZHU PHARMA CO., LTD.
    Inventors: Frank Wu, Aichen Wang